LUMOS DIAGNOSTICS HOLDINGS LIMITED (LDX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

LDX - LUMOS DIAGNOSTICS HOLDINGS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.74
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.105

21 Sep
2023

0.009

OPEN

$0.10

9.37%

HIGH

$0.11

17,123,891

LOW

$0.10

TARGET
$0.06 -42.9% downside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . HLA . IDX . IME . IMR . IPD . MEB . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
LDX: 1
Title FY20
Actual
FY21
Actual
FY22
Forecast
FY23
Forecast
EPS (cps) xxx - 12.4 - 20.1 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

N/A

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 20192020202120222023
EPS Basic xxxxxxxxxxxx-5.7
DPS All xxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxx15.7 M
Book Value Per Share xxxxxxxxxxxx4.6
Net Operating Cash Flow xxxxxxxxxxxx-14.3 M
Net Profit Margin xxxxxxxxxxxx-85.15 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20192020202120222023
Return on Capital Employed xxxxxxxxxxxx-66.22 %
Return on Invested Capital xxxxxxxxxxxx-43.75 %
Return on Assets xxxxxxxxxxxx-29.02 %
Return on Equity xxxxxxxxxxxx-66.22 %
Return on Total Capital xxxxxxxxxxxx-46.23 %
Free Cash Flow ex dividends xxxxxxxxxxxx-14.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20192020202120222023
Short-Term Debt xxxxxxxxxxxx3 M
Long Term Debt xxxxxxxxxxxx12 M
Total Debt xxxxxxxxxxxx15 M
Goodwill - Gross xxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxx5 M
Price To Book Value xxxxxxxxxxxx0.24

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20192020202120222023
Capex xxxxxxxxxxxx0.2 M
Capex % of Sales xxxxxxxxxxxx1.47 %
Cost of Goods Sold xxxxxxxxxxxx22 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxx9 M
Research & Development xxxxxxxxxxxx1 M
Investments - Total xxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

20/03/2023

1

Buy

$0.06

-42.86%

Bell Potter feels Lumos Diagnostics is demonstrating a shift towards a focus on services rather than product sales in a bid to drive revenue and profit increases. While total revenue was down at the company's half yearly report, services revenue lifted 4%.

Additionally, the company has signed three services agreements with Hologic that offer a potential US$2.5m in revenue, alongside four contracts for development programs with other customers. 

The Buy rating is retained and the target price decreases to $0.06 from $0.10.

FORECAST
Bell Potter forecasts a full year FY22 dividend of 0.00 cents and EPS of minus -20.10 cents.
Bell Potter forecasts a full year FY23 dividend of 0.00 cents and EPS of minus -8.70 cents.

LDX STOCK CHART